A study, which was conducted as part of the GUTBAT trial (NCT03290846) , has reported beneficial cardiac and renal effects of the hormone secretin . This is the first study to report the direct impact of secretin on myocardial glucose uptake and renal filtration. In recent times, gastrointestinal (GI) peptides are being studied for their potential cardiac-related therapeutic properties. Type 2 diabetes mellitus (T2DM) drugs, particularly the glucagon-like peptide (GLP-1) analogs, have shown promising results in reducing mortality in patients with cardiovascular diseases.
Secretin belongs to the same class of GI peptides as GLP-1. The study This study shows that secretin increases cardiovascular activity and renal filtration. Large-scale studies are required to validate these potential benefits of secretin and assess their use in developing novel therapeutics for individuals with…
